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ABSTRACT
Background: Warts are a common sight in Dermatology clinics
and they constitute the commonest cutaneous manifestation of
human papilloma virus (HPV) infection. A variety of procedures
has been used and treatment may be invasive and/or
conservative. Therefore, the aim of this study was to evaluate the
efficacy and safety of intralesional Candida antigen injection in
the treatment of common warts. Methods: At outpatient
Dermatology clinic, 28 patients with common warts of the hands
and feet were treated with intralesional Candida antigen. Side
effects as well as improvements in texture after each session and
after the final treatment were documented. The patients treated
by 0.1 intralesional candidal injection once weekly maximum for
5 sessions for 5 weeks or less if complete recovery occur.
Results: Patient’s response to treatment was assessed clinically
and we found disappearance of the wart and return of the normal
skin markings in 35.7% of patients following intralesional
candida injection. All reported side effects were mild, transient
and tolerable, and did not necessitate stoppage of treatment in
any of the studied patients. No recurrence reported during 6
months follow up. Conclusion: Intralesional Candida injection is
an effective and safe modality for the treatment of common
warts.
Keywords: Warts, Candida injections, Immunotherapy

INTRODUCTION
ommon warts or verrucae vulgaris
benign proliferations of the skin or
mucosa caused by human papilloma virus
(HPV) infection, they are commonly caused
by HPV-2 as it continue to form new genomic
variants and situated on the back of hands and
fingers but also may occur anywhere on the
skin [1]. Infection with HPV occurs by direct
skin contact with trauma sites. The incubation
period is about two to six months. Diagnosis
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is made by examination and typical features
observation. Investigations are not usually
used [2].
Warts are commonly treated by traditional
treatments as destructive procedures such as
cryotherapy,
electrocoagulation,
chemical
cautery,
and
laser.
All of these treatments can be painful; time
consuming or expensive and none of them is
considered the gold standard [3].
Candida is the first antigen that was tried
for immunotherapy of warts and was reported
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success in majority of patients. Candida
immunotherapy has even been reported in all
body warts even genital warts and also in
children with recalcitrant warts [4].
The present study was aimed to evaluate
the efficacy and safety of intralesional
Candida antigen injection in the treatment of
common warts.
METHODS
The present study was carried at
Dermatology, Venereology and Andrology
department, Zagazig University Hospitals. All
patients were recruited from Dermatology,
Venereology and Andrology outpatient clinics
of Zagazig University Hospitals in the period
from February 2017 to February 2018.
The present study included 28 adult
patients of both sexes with common warts of
different sites, sizes and durations and no
concurrent use of systemic or topical
treatments
of warts.
After excluding
hypersensitivity patients to Candida antigen,
acute febrile illness, and immunosuppressive
diseases e.g. systemic lupus erythematosus,
concomitant
immunosuppressive
drugs
intake, past history of allergic skin disorders
such as generalized eczema or urticarial and
history
of meningitis
or
convulsions,
pregnancy and lactation.
Written informed consent was obtained
from all participants and the study was
approved by the research ethical committee of
Faculty of Medicine, Zagazig University. The
work has been carried out in accordance with
The Code of Ethics of the World Medical
Association (Declaration of Helsinki) for
studies involving humans.
Patients were subjected to history taking
regarding
age
and
sex,
history of
dermatological disease: including, onset,
course, duration, site, and history of previous
treatment for the disease, and history of
associated other dermatological diseases, and
history of systemic diseases and drug intake.
Local examination of warts to determine the
type, number, size, sites of warts and the
presence or absence of distant lesions. The
diagnosis of warts was made by clinical
examination, and patients were advised not to
use any other wart treatment during the study
period.
Amani N., et al..
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All patients were directly injected with 0.1
ml of Candida antigen (Candida albicans 1:20
w/v 10 ml vial) was brought from Allergy
Laboratories, INC. Oklahoma City, USA) into
the largest wart using an insulin syringe,
which is held parallel to the skin surface with
the bevel facing upward. Injections were done
at 1-week intervals until complete clearance
was achieved or for a maximum of ﬁve
treatment sessions. Response to treatment in
both groups was evaluated by the decrease in
size of warts and photographic comparison at
base line and at each visit. Immediate and late
adverse effects of both antigens were also
evaluated after each treatment session.
The results were evaluated as follows;
Complete response: disappearance of the wart
and return of the normal skin markings.
Partial response: 50-99% reduction in wart
size and no response: 0-49% decrease in wart
size [5]. Follow up evaluation was done every
month for six months after completion of the
treatment for detection of any wart
recurrence.
Statistical analysis
All data were collected, tabulated and
statistically analyzed using SPSS 24.0 for
windows (SPSS Inc., Chicago, IL, USA).
Data were tested for normal distribution using
the Shapiro Walk test. Qualitative data were
represented as frequencies and relative
percentages. Chi square test (χ2) and Fisher
exact was used to calculate difference
between qualitative variables as indicated.
Quantitative data were expressed as mean ±
SD (Standard deviation) for parametric and
median and range for non-parametric data.
Independent T test and Mann Whitney test
were used to calculate difference between
quantitative variables in two groups for
parametric and non-parametric variables
respectively. All statistical comparisons were
two tailed with significance Level of P-value
≤ 0.05 indicates significant, p <0.001
indicates highly significant difference while,
P> 0.05 indicates Non-significant difference.
RESULTS
The 28 patients included 8 males and 20
females with ages ranged from 18 to 56 years
old, with a mean of 33.36 ± 14.37 years old,
22 patients of them were on previous therapy;
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6 patients were on Cryo-cautery, 8 chemical
cautery, 4 electro- cautery, 2 immunotherapy
and 2 surgery before starting this study.
Clinical data of all patients are shown in table
1. The significant reduction appeared from 4 th
session with (35.7%) for complete response

and (64.3%) of patients showed partial
response as shown in table 2 and figures 2&3.
Side effects as burning sensation, edema and
erythema were mild, tolerable, and transient
as shown in figure 1.

Table 1. Clinical data of the warts of the patients ( results section ).
Variable
Warts site n (%)

Studied patients
(n=28)

Dorsum of Rt hand
Dorsum of Lt hand
Dorsum of both
hand
Periungual
Dorsum of Rt foot
Dorsum of Lt foot

6 (21.4)
8 (28.6)
2 (7.1)
4 (14.3)
6 (21.4)
2 (7.1)
17 (3 – 32)

Duration (months)
Median (Range)
Recalcitrant, n (%)
Warts size

n (%)

12 (42.9)
< 1 cm
> 1 cm

Table 2. Therapeutic response among the patients ( results section ).
Response
1st Session
n (%)
nd
2 Session
n (%)
3rd Session
n (%)
4th Session
n (%)
5th Session
n (%)
Final results
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24 (85.7)
4 (14.3)

Studied patients
(n=28)

No response
Partial response
Partial response
Complete
response
Partial response
Complete
response
Partial response
Complete
response
Partial response
Complete
response
No response
partial response
Complete response
10(35.7)

6 (21.4)
22 (78.6)
28 (100)
--28 (100)
--24 (85.7)
4 (14.3)
18 (75)
6 (25)
--18 (64.3)
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Table 3. Relation between the therapeutic response and demographic & clinical data ( results
section ).
Partial
Complete
P
response
response
(N=18)
(N=10)
Age (years)
36.11 ± 15.19
28.4 ± 12.7
.641
Mean ± SD
Female, n (%)
12 (66.7)
8 (80)
.600
Duration (months)
19.33 ± 7.81
11.2 ± 12.01
.04
Mean ± SD
Previous therapy, n (%)
16 (88.9)
4 (40)
.060
Size, n (%)
< 1 cm
1 (25)
7 (53.8)
.650
> 1 cm
3 (75)
-Recalcitrant
12 (66.7)
--.02
Table 4. The most common immunotherapeutic methods for the treatment of warts ( discussion
section )
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Figure 2. Partial response of common wart after 5 sessions of intralesional candida antigen
injection

Figure 3. Complete response of common wart after 5 sessions of intralesional candida antigen
injection.
DISCUSSION
Warts treatment represents a challenge
for both patients and physicians. Most of the
current procedures such as cryotherapy,
electrodessication and laser therapy depend
on the ablation of warts, and they are
commonly associated with significant pain,
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tissue destruction and high recurrence rate
[3,5,6]
.
Several immunotherapeutic agents have
been used for the treatment of warts to
overcome the challenges associated with the
use of destructive therapies. Among these
agents,
is
intralesional
antigen
immunotherapy that has shown a promising
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efficacy and safety in the treatment of
different types of warts [7-9].
Based on the previous observations, we
designed our study to evaluate the efficacy
and safety of one of the effective
immunotherapeutic
agent,
intralesional
Candida antigen in the treatment of common
warts.
The various immunotherapeutic agents
used for the treatment of different types of
warts. The immunotherapeutic agents were
classified according to the mode of
administration into three main categories topical, intralesional, and systemic as shown
in table 4 [14].
In the current work, we did not make a
pre-sensitization skin test for candida antigen
because of the high incidence of Candia
infection in our community makes the
sensitivity to the injected Candida antigen
highly expected.
Collectively, the study revealed complete
response was achieved in 35.7% of the
studied patients, while partial response was
reported in the other 64.3% of patients with
no recurrence in the 6- month follow-up
period. This rate of success was lower than
that reported by Clifton et al. [10] (47%),
Alikhan et al. [11] (39%) and Nofal et al. [5]
(61.1%), but it was higher than reported by
Nofal et al. [12] (33.3%).
Factors which may explain the different
response to candida antigen; the differences in
the studied population selected for treatment,
the studied patients number, the injected
antigen sensitivity degree, and the warts
number, type, duration and resistance may be
responsible for the difference between the
results of our study and other studies.
In this study, no statistically significant
relationship
was
found
between
the
therapeutic response to candida antigen
injection, and the different clinical variables,
including age, sex, site, type, size or previous
therapy of warts, but a significant inverse
relationship
was
found
between
the
therapeutic response and disease duration (the
shorter the duration of warts, the higher the
response) (as illustrated in table 3). In
consistency with our results, Nofal et al. [5]
reported comparable findings. This finding
Amani N., et al..
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may be attributed to the higher viral load
expected to increase with the longer duration
of the warts. In addition recalcitrant warts
showed poor response than non-recalcitrant
types.
This study revealed clearance of
untreated warts, including the nearby and
distant lesions. This observation comes in
agreement with those reported by other
studies utilizing intralesional antigen injection
for the treatment of warts [4]. Also, Alikhan et
al. [11] (39%) and Clifton et al. [10] (47%) were
similar to our results. This strongly indicates
the development of a widespread cellmediated immunity against HPV as a
response to candida antigen injection; an
observation that represents a great advantage
of Candida
antigens
over
traditional
procedures.
In our study, all reported side effects as
burning sensation, edema, erythema and flulike symptoms were mild, tolerable, and
transient and did not necessitate stoppage of
treatment in any of the studied patients. These
findings were in agreement with studies done
by Clifton et al. [10] and Nofal et al. [5]
In the present study, no recurrence was
observed in any of the studied patients after
the 6-month follow-up period. Similar
observations have also been reported by
similar related studies with Candida antigen
done by Maronn et al. [13] and Nofal et al. [5,
12]
This finding represents an important and
promising advantage of candida antigen
immunotherapy over traditional modalities.
In addition to Fathy et al. [15] reported the
beneficial role of intralesional Candida
antigen injection in multiple recalcitrant
plantar warts as a simple, safe, effective
treatment modality with minimal side effects,
very low recurrence rate.
CONCLUSION
Intralesional Candida injection is an
effective and safe therapy for common warts
treatment.
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